Telitacicept injection
Sponsors
Remegen Co. Ltd., Remegen Co. Ltd., Vor Biopharma Inc., Remegen Co. Ltd.
Conditions
Generalized Myasthenia GravisModerately to Severely Active Systemic Lupus Erythematosus
Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 2-Stage Trial to Evaluate Efficacy and Safety of Telitacicept Compared to Placebo in Patients with Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)
CompletedCTIS2022-500445-24-00
Start: 2022-11-30End: 2025-01-31Target: 146Updated: 2025-01-21
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study with an Open-label Extension Period to Evaluate the Efficacy and Safety of Telitacicept in Patients with Generalized Myasthenia Gravis
RecruitingCTIS2024-512126-29-00
Start: 2025-02-25Target: 72Updated: 2025-10-02
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Telitacicept Compared to Placebo in Patients with Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2)
WithdrawnCTIS2024-512716-21-00
Target: 63Updated: 2025-01-21